Clinical trials: Myeloid Tumor
Acute Myeloid Leukemia
Study of GDX012 in Patients With MRD Positive AML
The purpose of this first-in-human study is to assess the safety, tolerability, antileukemic activity and maximum tolerated dose (MTD) of GDX012 in AML patients who are MRD positive by multiparametric flow cytometry.
- Trial name
- NCT05001451
- Testing
- GDX012 Suspension for IV Infusion
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- GammaDelta Therapeutics Limited
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
The purpose of this study is to test the safety of selinexor (KPT-330) and to find the highest dose of selinexor (KPT-330) that can be given safely when it is combined with two chemotherapy drugs (fludarabine and cytarabine).
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS), Mixed Phenotype Acute Leukemia (MPAL)
- Trial name
- NCT02212561
- Testing
- Selinexor, Fludarabine, Cytarabine
- Where
- 6 sites in United States
- Volunteers
- 19 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia
The current understanding of PR104 justifies the evaluation of PR104 in subjects with relapsed/refractory AML and ALL. These include: Hypoxia.
- Trial name
- NCT01037556
- Testing
- PR104
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Proacta, Incorporated
Hematologic Malignancies
Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies
This is a phase II study to assess the day 180 event free and overall survival after administration of a specified combination of fludarabine, busulfan, Total Body Irradiation (TBI), and thymoglobulin reduced intensity…
- Trial name
- NCT01622556
- Testing
- Fludarabine, Busulfan, Thymoglobulin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Virginia
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations
To evaluate the safety and effectiveness of Sodium Stibogluconate in the treatment of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) with p53 mutation from a defined list.
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myeloid Malignancy, Temperature-Sensitive p53 Mutation
- Trial name
- NCT04906031
- Testing
- Sodium stibogluconate
- Where
- China
- Volunteers
- 5 people
- Sponsor
- First Affiliated Hospital of Jinan University
Leukemia
A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
The purpose of this clinical research study is to compare the rate of complete cytogenetic response of dasatinib to imatinib therapy at 6 months after randomization in chronic phase CML patients.
- Trial name
- NCT00362466
- Testing
- Dasatinib, Imatinib
- Where
- 45 sites in United States
- Volunteers
- 3 people
- Sponsor
- Bristol-Myers Squibb
Acute Myeloid Leukemia
A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia
The purpose of this observational study is to assess the real-world safety of maintenance therapy with oral azacitidine in Korean participants with acute myeloid leukemia (AML) who achieved first complete remission (CR) or…
- Trial name
- NCT06073769
- Testing
- Oral azacitidine
- Where
- 2 sites in South Korea
- Volunteers
- 154 people
- Sponsor
- Bristol-Myers Squibb
Leukemia, Myelodysplastic Syndromes
Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes
RATIONALE: Photopheresis treats the patient's blood with drugs and ultraviolet light outside the body and kills the white blood cells.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00045305
- Testing
- Cyclosporine, Methotrexate, Photopheresis
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Eastern Cooperative Oncology Group
AML
Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)
Open-label, multi-dose, single-arm, multi-center, Phase 1/2 study conducted in three segments: the Single Patient Dose Escalation Segment (complete), followed by the Multi-Patient Dose Escalation Segment (complete) and the…
- Trial name
- VOYAGE (NCT02152956)
- Testing
- Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
- Where
- 43 sites in United States, France and 6 more
- Volunteers
- 244 people
- Sponsor
- MacroGenics
Acute Promyelocytic Leukemia
Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)
The investigators design a multicenter randomized controlled trial to prove that RIF plus ATRA is possibly superior to ATO plus ATRA as consolidation and maintenance treatment for the patients with non-high-risk APL.
- Trial name
- APL16 (NCT02899169)
- Testing
- Realgar-Indigo naturalis formula, all-trans retinoic acid, Arsenic trioxide
- Where
- China
- Volunteers
- 110 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Relapsed or Refractory Acute Myeloid Leukemia
Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia
Recent preclinical and retrospective clinical data have suggested that dexamethasone might sensitize leukemic cells to chemotherapy-induced cell death and thus limit the risk of leukemic regrowth and relapse.
- Trial name
- DEXAML-03 (NCT03765541)
- Testing
- Dexamethasone, Amsacrine, Cytarabine
- Where
- 10 sites in France
- Volunteers
- 73 people
- Sponsor
- University Hospital, Toulouse
Leukemia, Myelodysplastic Syndromes
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have relapsed or…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00049686
- Testing
- laromustine
- Where
- United States
- Sponsor
- Vion Pharmaceuticals
Chronic Myeloid Leukemia
The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder
Research Hypothesis: Treatment with dasatinib 100 mg QD is superior to imatinib 600 mg QD in terms of complete cytogenetic response (CCyR) in chronic phase (CP) Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia…
- Trial name
- NCT00854841
- Testing
- Dasatinib and Imatinib
- Sponsor
- Pusan National University Hospital
Leukemia, Myelocytic, Acute, Myelodysplastic Syndromes
Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)
This trial is in high risk patients to determine the safety and efficacy of posaconazole vs. fluconazole in the prophylaxis against development of invasive fungal infections.
- Conditions
- Leukemia, Myelocytic, Acute, Myelodysplastic Syndromes, Neutropenia
- Trial name
- NCT00044486
- Testing
- Posaconazole oral suspension
- Volunteers
- 602 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Myeloid Leukemia
Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
The goal of this clinical research study is to find out if treatment with a combination of dasatinib plus ropeginterferon can help to control CML-CP. The safety of this combination will also be studied.
- Trial name
- NCT07269470
- Testing
- Dasatinib, Ropeginterferon alfa-2b (P1101)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)
7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
This phase I trial is studying the side effects and best dose of 7-hydroxystaurosporine when given together with perifosine in treating patients with relapsed or refractory acute leukemia, chronic myelogenous leukemia, or…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00301938
- Testing
- 7-hydroxystaurosporine, perifosine, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
This research is a phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational intervention to learn whether it works in treating a specific cancer.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01643668
- Testing
- Busulfan, Clofarabine, Allogeneic Stem Cell Infusion
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
Acute Myeloid Leukemia
Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML
This is a research study of ribavirin which will be given in combination with vismodegib and/or decitabine. The purpose of this study is to see if patients respond to treatment when ribavirin is given with vismodegib alone or in…
- Trial name
- NCT02073838
- Testing
- Ribavirin, Vismodegib, Decitabine
- Where
- Canada
- Volunteers
- 23 people
- Sponsor
- Sarit Assouline
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
This pilot phase II trial studies how well giving vorinostat, tacrolimus, and methotrexate works in preventing graft-versus-host disease (GVHD) after stem cell transplant in patients with hematological malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01789255
- Testing
- vorinostat, tacrolimus, cyclosporine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Syndrome (hrMDS).
- Trial name
- NCT04278768
- Testing
- Emavusertib, Venetoclax
- Where
- 32 sites in United States, Czechia and 6 more
- Volunteers
- 366 people
- Sponsor
- Curis, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.